empoweringmuscleempoweringlives
Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function.
cardiovascular disease
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
NEUROMUSCULAR DISEASE
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
Press Releases
- Cytokinetics Releases Inaugural Corporate Responsibility Report
- Cytokinetics to Participate in Upcoming Investor Conferences
- Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Cytokinetics Corporate Presentation
Pipeline
We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, aficamten, and CK-136.
Careers
We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.